2-氨基-3-(4-羟基-3-甲氧基苯基)丙酸结构式
|
常用名 | 2-氨基-3-(4-羟基-3-甲氧基苯基)丙酸 | 英文名 | (DL)-3-O-Methyldopa |
---|---|---|---|---|
CAS号 | 7636-26-2 | 分子量 | 211.214 | |
密度 | 1.3±0.1 g/cm3 | 沸点 | 407.3±45.0 °C at 760 mmHg | |
分子式 | C10H13NO4 | 熔点 | N/A | |
MSDS | N/A | 闪点 | 200.1±28.7 °C |
2-氨基-3-(4-羟基-3-甲氧基苯基)丙酸用途3-O-甲基-DL-DOPA是一种存在于脑脊液中的内源性代谢产物,可用于研究癫痫、嘌呤核苷磷酸化酶缺乏症和芳香L氨基酸脱羧酶缺乏症[1][2][3][4]。 |
中文名 | 2-氨基-3-(4-羟基-3-甲氧基苯基)丙酸 |
---|---|
英文名 | 2-Amino-3-(4-hydroxy-3-methoxyphenyl)propanoic acid |
中文别名 | 3-甲氧基酪氨酸 | 3-O-甲基多巴 | 3-(4-羟基-3-甲氧基苯基)丙氨酸 |
英文别名 | 更多 |
描述 | 3-O-甲基-DL-DOPA是一种存在于脑脊液中的内源性代谢产物,可用于研究癫痫、嘌呤核苷磷酸化酶缺乏症和芳香L氨基酸脱羧酶缺乏症[1][2][3][4]。 |
---|---|
相关类别 | |
体外研究 | 内源性代谢产物被定义为《京都基因和基因组百科全书》注释为我们基因组中约1900种代谢酶的底物或产物。在文献正文中很清楚,许多这些代谢产物都具有毒性[1]。 |
参考文献 |
密度 | 1.3±0.1 g/cm3 |
---|---|
沸点 | 407.3±45.0 °C at 760 mmHg |
分子式 | C10H13NO4 |
分子量 | 211.214 |
闪点 | 200.1±28.7 °C |
精确质量 | 211.084457 |
PSA | 92.78000 |
LogP | 0.08 |
蒸汽压 | 0.0±1.0 mmHg at 25°C |
折射率 | 1.591 |
储存条件 | 室温,密闭,干燥 |
风险声明 (欧洲) | 22-36/37/38 |
---|---|
安全声明 (欧洲) | 22-26-36/37/39 |
危险品运输编码 | NONH for all modes of transport |
~% 2-氨基-3-(4-羟基-3-... 7636-26-2 |
文献:Journal of the Chemical Society, , p. 1692,1694 |
~% 2-氨基-3-(4-羟基-3-... 7636-26-2 |
文献:Journal of Organic Chemistry, , vol. 23, p. 27,32 |
~% 2-氨基-3-(4-羟基-3-... 7636-26-2 |
文献:Journal of the Chemical Society, , p. 1795,1799 |
~% 2-氨基-3-(4-羟基-3-... 7636-26-2 |
文献:Journal of the Chemical Society, , p. 1692,1694 |
~% 2-氨基-3-(4-羟基-3-... 7636-26-2 |
文献:Journal of the Chemical Society, , p. 1795,1799 |
~% 2-氨基-3-(4-羟基-3-... 7636-26-2 |
文献:Journal of the American Chemical Society, , vol. 35, p. 1611 |
2-氨基-3-(4-羟基-3-甲氧基苯基)丙酸上游产品 7 | |
---|---|
2-氨基-3-(4-羟基-3-甲氧基苯基)丙酸下游产品 0 |
Cysteinyl-glycine reduction as marker for levodopa-induced oxidative stress in Parkinson's disease patients.
Mov. Disord 26 , 543-546, (2011) Oxidative stress is influenced by the thiol homeostasis, which determines the redox milieu. One of its components is Cysteinyl-glycine (Cys-Gly) generation, as its metabolic precursor is the free radi... |
|
Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Clin. Neuropharmacol. 33(3) , 135-41, (2010) The aims of the present study were to investigate the pharmacokinetic and pharmacodynamic (pk/pd) relationship of levodopa (l-dopa) in patients with advanced Parkinson disease (PD) and also to evaluat... |
|
Levodopa infusion combined with entacapone or tolcapone in Parkinson disease: a pilot trial.
Eur. J. Neurol. 19(6) , 820-6, (2012) Catechol-O-methyltransferase inhibitors may be used to decrease levodopa requirement. The objective was to investigate whether the levodopa/carbidopa intestinal gel infusion dose can be reduced by 20%... |
3-Methoxytyrosine |
3-Methoxy-D,L-tyrosine |
2-amino-3-(4-hydroxy-3-methoxyphenyl)propanoic acid |
3-Methoxy-tyrosine |
Tyrosine, 3-methoxy- |
3-METHOXY-DL-TYROSINE |
UNII:SO86T1OB2P |
3-O-Methyldopa |